The FDA has approved a 12.5-mg tablet formulation of the thiazide-like diuretic chlorthalidone ( HemiClor – Ingenus) for treatment of hypertension. Chlorthalidone has been available for years in 15-, 25-,…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):118 doi:10.58347/tml.2025.1733e
The FDA has approved a 12.5-mg tablet formulation of the thiazide-like diuretic chlorthalidone ( HemiClor – Ingenus) for treatment of hypertension. Chlorthalidone has been available for years in 15-, 25-, and 50-mg tablets ( Thalitone , and generics) and in fixed-dose combinations with azilsartan medoxomil (Edarbyclor) and atenolol ( Tenoretic , and generics).
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…
Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2020 May 18; 62(1598):73-80
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2017 Mar 13; 59(1516):41-8
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of…
Med Lett Drugs Ther. 2016 Sep 12; 58(1503):115-7
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation…
Treat Guidel Med Lett. 2014 May; 12(141):31-8
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation threshold and treatment target; this higher target is controversial, except in patients ≥80 years old.
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for…
Treat Guidel Med Lett. 2012 Jan; 10(113):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs…
Treat Guidel Med Lett. 2009 Jan; 7(77):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines ( volume 1, page 19, December 2002 ) and in The Medical Letter ( volume 50, page 73, September 22, 2008 ).
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs…
Treat Guidel Med Lett. 2005 Jun; 3(34):39-48
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs…
Treat Guidel Med Lett. 2003 Feb; 1(6):33-40
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.